Literature DB >> 22710073

DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.

Christopher Korch1, Monique A Spillman, Twila A Jackson, Britta M Jacobsen, Susan K Murphy, Bruce A Lessey, V Craig Jordan, Andrew P Bradford.   

Abstract

OBJECTIVES: Cell lines derived from human ovarian and endometrial cancers, and their immortalized non-malignant counterparts, are critical tools to investigate and characterize molecular mechanisms underlying gynecologic tumorigenesis, and facilitate development of novel therapeutics. To determine the extent of misidentification, contamination and redundancy, with evident consequences for the validity of research based upon these models, we undertook a systematic analysis and cataloging of endometrial and ovarian cell lines.
METHODS: Profiling of cell lines by analysis of DNA microsatellite short tandem repeats (STR), p53 nucleotide polymorphisms and microsatellite instability was performed.
RESULTS: Fifty-one ovarian cancer lines were profiled with ten found to be redundant and five (A2008, OV2008, C13, SK-OV-4 and SK-OV-6) identified as cervical cancer cells. Ten endometrial cell lines were analyzed, with RL-92, HEC-1A, HEC-1B, HEC-50, KLE, and AN3CA all exhibiting unique, uncontaminated STR profiles. Multiple variants of Ishikawa and ECC-1 endometrial cancer cell lines were genotyped and analyzed by sequencing of mutations in the p53 gene. The profile of ECC-1 cells did not match the EnCa-101 tumor, from which it was reportedly derived, and all ECC-1 isolates were genotyped as Ishikawa cells, MCF-7 breast cancer cells, or a combination thereof. Two normal, immortalized endometrial epithelial cell lines, HES cells and the hTERT-EEC line, were identified as HeLa cervical carcinoma and MCF-7 breast cancer cells, respectively.
CONCLUSIONS: Results demonstrate significant misidentification, duplication, and loss of integrity of endometrial and ovarian cancer cell lines. Authentication by STR DNA profiling is a simple and economical method to verify and validate studies undertaken with these models.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22710073      PMCID: PMC3432677          DOI: 10.1016/j.ygyno.2012.06.017

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  97 in total

1.  Biologists tackle cells' identity crisis.

Authors:  Alla Katsnelson
Journal:  Nature       Date:  2010-06-03       Impact factor: 49.962

Review 2.  The costs of using unauthenticated, over-passaged cell lines: how much more data do we need?

Authors:  Peyton Hughes; Damian Marshall; Yvonne Reid; Helen Parkes; Cohava Gelber
Journal:  Biotechniques       Date:  2007-11       Impact factor: 1.993

3.  Widespread intraspecies cross-contamination of human tumor cell lines arising at source.

Authors:  R A MacLeod; W G Dirks; Y Matsuo; M Kaufmann; H Milch; H G Drexler
Journal:  Int J Cancer       Date:  1999-11-12       Impact factor: 7.396

4.  Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors.

Authors:  P J DiSaia; J G Sinkovics; F N Rutledge; J P Smith
Journal:  Am J Obstet Gynecol       Date:  1972-12-01       Impact factor: 8.661

Review 5.  Molecular and pathologic aspects of endometrial carcinogenesis.

Authors:  Jonathan L Hecht; George L Mutter
Journal:  J Clin Oncol       Date:  2006-10-10       Impact factor: 44.544

Review 6.  Cross-contamination of cells in culture.

Authors:  W A Nelson-Rees; D W Daniels; R R Flandermeyer
Journal:  Science       Date:  1981-04-24       Impact factor: 47.728

7.  ED(27) trophoblast-like cells isolated from first-trimester chorionic villi are genetically identical to HeLa cells yet exhibit a distinct phenotype.

Authors:  D A Kniss; Y Xie; Y Li; S Kumar; E A Linton; P Cohen; P Fan-Havard; C W G Redman; I L Sargent
Journal:  Placenta       Date:  2002-01       Impact factor: 3.481

Review 8.  Microsatellite instability and DNA mismatch repair deficiency testing in hereditary and sporadic gastrointestinal cancers.

Authors:  Adrian Gologan; Antonia R Sepulveda
Journal:  Clin Lab Med       Date:  2005-03       Impact factor: 1.935

9.  KLE: a cell line with defective estrogen receptor derived from undifferentiated endometrial cancer.

Authors:  G S Richardson; G R Dickersin; L Atkins; D T MacLaughlin; S Raam; L P Merk; F M Bradley
Journal:  Gynecol Oncol       Date:  1984-02       Impact factor: 5.482

10.  Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.

Authors:  C A Hills; L R Kelland; G Abel; J Siracky; A P Wilson; K R Harrap
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

View more
  108 in total

Review 1.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

2.  Genetic polymorphisms in CDH1 are associated with endometrial carcinoma susceptibility among Chinese Han women.

Authors:  Yue-Hang Geng; Zi-Fan Wang; Yu-Mian Jia; Li-Yuan Zheng; Lan Chen; Dong-Ge Liu; Xiang-Hong Li; Xin-Xia Tian; Wei-Gang Fang
Journal:  Oncol Lett       Date:  2018-09-20       Impact factor: 2.967

3.  Reproducibility: changing the policies and culture of cell line authentication.

Authors:  Leonard P Freedman; Mark C Gibson; Stephen P Ethier; Howard R Soule; Richard M Neve; Yvonne A Reid
Journal:  Nat Methods       Date:  2015-06       Impact factor: 28.547

4.  Local remodeling of synthetic extracellular matrix microenvironments by co-cultured endometrial epithelial and stromal cells enables long-term dynamic physiological function.

Authors:  Christi D Cook; Abby S Hill; Margaret Guo; Linda Stockdale; Julia P Papps; Keith B Isaacson; Douglas A Lauffenburger; Linda G Griffith
Journal:  Integr Biol (Camb)       Date:  2017-04-18       Impact factor: 2.192

5.  Rapid estrogen signaling negatively regulates PTEN activity through phosphorylation in endometrial cancer cells.

Authors:  Melanie M Scully; Leslie K Palacios-Helgeson; Lah S Wah; Twila A Jackson
Journal:  Horm Cancer       Date:  2014-05-21       Impact factor: 3.869

Review 6.  The Estrogen Receptor α-Cistrome Beyond Breast Cancer.

Authors:  Marjolein Droog; Mark Mensink; Wilbert Zwart
Journal:  Mol Endocrinol       Date:  2016-08-04

7.  Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel.

Authors:  Christopher Breed; Douglas A Hicks; Patricia G Webb; Carly E Galimanis; Benjamin G Bitler; Kian Behbakht; Heidi K Baumgartner
Journal:  Mol Cancer Res       Date:  2019-01-03       Impact factor: 5.852

8.  Discovery of HeLa Cell Contamination in HES Cells: Call for Cell Line Authentication in Reproductive Biology Research.

Authors:  Douglas A Kniss; Taryn L Summerfield
Journal:  Reprod Sci       Date:  2014-02-11       Impact factor: 3.060

9.  Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.

Authors:  Diana M Cittelly; Irina Dimitrova; Erin N Howe; Dawn R Cochrane; Annie Jean; Nicole S Spoelstra; Miriam D Post; Xian Lu; Russell R Broaddus; Monique A Spillman; Jennifer K Richer
Journal:  Mol Cancer Ther       Date:  2012-10-16       Impact factor: 6.261

Review 10.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.